What is Emergent?
Emergent BioSolutions Inc. is a prominent life sciences entity headquartered in Gaithersburg, Maryland, dedicated to providing critical preparedness and response solutions for public health threats. The company's diverse portfolio includes emergency treatments for opioid overdose (NARCAN Nasal Spray), vaccines for cholera and typhoid fever (Vaxchora, Vivotif), and countermeasures for anthrax (Anthrasil, BioThrax, CYFENDUS, Raxibacumab). Additionally, Emergent offers vaccines and treatments for smallpox (ACAM2000, TEMBEXA), Ebola (Ebanga), and botulism (BAT), alongside specialized decontamination products. Their development pipeline is robust, featuring potential treatments for nerve agent poisoning, Lassa fever, Marburg virus disease, and Sudan virus disease, among others. Beyond its product offerings, Emergent provides comprehensive contract development and manufacturing services, supporting drug substance and product manufacturing, packaging, and process development. The company was incorporated in 1998.
How much funding has Emergent raised?
Emergent has raised a total of $62.5M across 1 funding round:
Stock Offering
$62.5M
Stock Issuance/Offering (2006): $62.5M, investors not publicly disclosed
What's next for Emergent?
The recent major strategic investment into Emergent BioSolutions Inc. suggests a focus on accelerating the development and deployment of its advanced public health countermeasures and vaccines. This capital infusion is likely to bolster research and development efforts for its pipeline candidates, such as those targeting nerve agent poisoning and emerging viral threats. Furthermore, the funding may support the expansion of its manufacturing capabilities and the strengthening of its supply chain to meet national and international demand for biodefense solutions. Emergent's strategic positioning in the preparedness and response market, coupled with this significant financial backing, indicates a commitment to addressing critical public health challenges and solidifying its role as a key player in biosecurity.
See full Emergent company page
